Nuvectis Pharma Expands Board Of Directors, Welcomes Biotech Executive Juan Sanchez, MD

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company developing precision medicines for oncology, announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a highly experienced biotech executive whose career spans more than three decades, combining expertise in medicine, capital markets, and the biopharmaceutical industry. His appointment adds valuable insight and leadership to Nuvectis as it advances its pipeline of therapies addressing serious unmet needs in cancer treatment.

Dr. Sanchez most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, a company acquired by Johnson & Johnson in April 2025 for $14.6 billion. During his tenure, which began in 2014, he played an important role in the company’s growth, supporting the clinical development and successful commercialization of CAPLYTA (lumateperone), a major milestone in the company’s evolution.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, stated, "We are excited to welcome Dr. Juan Sanchez to the Nuvectis Board of Directors. As we enter the next stage of growth, with the start of the Phase 1b program for NXP900, we believe Juan brings a wealth of industry and strategic expertise and experience that will bring significant value to Nuvectis and contribute to the potentially bright future that we envision for the Company."

Dr. Sanchez mentioned, "I am pleased to join the Nuvectis Board at this pivotal time for the Company. The Company's innovative approach to developing NXP900 for the potential use in advanced and treatment-resistant cancers, and the prospect of working with the seasoned management team and Board members, made the opportunity to join the Board compelling.”

Before joining Intra-Cellular Therapies, Dr. Sanchez built extensive experience in healthcare equity research on Wall Street. He worked as a managing director at Ladenburg Thalmann & Co. and earlier at Punk, Ziegel & Co., where he analyzed biopharma companies and gained deep insights into the intersection of science, business, and capital markets. Earlier in his career, he practiced medicine for five years in Colombia, providing him with direct patient care experience that continues to inform his perspective on medical innovation.

Dr. Sanchez holds a Doctor of Medicine degree from Pontifical Xavierian University in Bogotá, Colombia. He also earned an MBA from the University of Los Andes in Colombia and a Master’s degree in International Affairs from Columbia University in New York. His diverse background spanning clinical practice, investment research, and corporate leadership positions him as a strong addition to Nuvectis Pharma’s Board as the company works to advance its oncology pipeline.